Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma

por Nagpal, Seema, Recht, Cathy Kahn, Bertrand, Sophie, Thomas, Reena Parada, Ajlan, Abdulrazag, Pena, Justine, Gershon, Megan, Coffey, Gwen, Kunz, Pamela L., Li, Gordon, Recht, Lawrence D.
Publicado 2015